Newark-based BioCentriq Inc., a cell and gene therapy contract development and manufacturing organization, named David Smith as its new vice president of development, according to a Tuesday announcement.
With 15-plus years of experience in the field of regenerative medicine, Smith’s proven expertise and background in process development and engineering have led to a history of success in advancing cell therapy product manufacturing. His skills and experience include design of experiments, quality-by-design, research & development, data analysis, strong leadership and crossfunctional oversight, among many others. In his new role at BioCentriq, he will lead manufacturing, science & technology, process development and analytical method development.
As the former vice president of technical operations at Ori Biotech, Smith led the execution of the technical strategy for Ori’s first innovative technology play in cell therapy manufacturing. He was charged with ensuring the approach remained relevant to industry needs as it matured, taking a multipronged approach to identify industry needs, align to viable solutions, build a cross-functional team and support adoption.
“We’re excited to welcome David to BioCentriq,” CEO Haro Hartounian said. “His extensive experience, deep industry knowledge and demonstrated success of leading operations and development initiatives will help us continue to address market and client demand.”
Smith’s other prior roles include serving as director of research and development at Minaris Regenerative Medicine.
Smith has his Ph.D. in regenerative medicine from Loughborough University, and he has sat on numerous committees.